Clinical trial · no report yet · Phase 3
VERSATILE-003
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- NCT06790966 ↗
- Terminated
- PDS Biotechnology Corp.
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| YouTube | 2 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Open-Label, Randomized Study of PDS0101 and Pembrolizumab vs Pembrolizumab Alone in First-Line Treatment of Unresectable Recurrent and/or Metastatic HPV16+ Head and Neck Squamous Cell Carcinoma
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Recurrent Head and Neck Cancer; Metastatic Head and Neck Cancer; HPV Positive Oropharyngeal Squamous Cell Carcinoma; Neoplasms, Head and Neck; Unresectable Head and Neck Squamous Cell Carcinoma
- Interventions
- Combination Treatment of PDS0101 and Pembrolizumab; Pembrolizumab Monotherapy
- Arms
- Interventional Arm · Experimental
- Control Arm · Active comparator
- Enrollment
- 12
- Primary outcomes
- Overall Survival (OS)
- Progression-Free Survival (PFS)
- Sponsor
- PDS Biotechnology Corp.
- Start
- May 30, 2025
- Primary completion
- Aug 25, 2026
- Results posted
- No
- Registry record
- NCT06790966 · updated Sep 2, 2026